Page 11234..10..»

Archive for the ‘Global News Feed’ Category

George Archos Reports Holdings in Verano Holdings Corp.

Sunday, February 14th, 2021

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- George Archos (the “Acquiror”), the Chairman, CEO and a director of Verano Holdings Corp. (“Verano”), has ownership of 14,226,545.0366 subordinate voting shares of Verano (“SV Shares”), representing 11.32% of the issued and outstanding SV Shares, and 426,796.3508 proportionate voting shares of Verano (“PV Shares”) representing 25.79% of the issued and outstanding PV Shares held directly and indirectly through Copperstone Trust, 3PLGK, LLC, Archos Capital Group, LLC and GP Management Group, LLC (the “Related Entities”). On an as-converted basis, George Archos holds 19.62% of the issued and outstanding SV Shares of Verano. This is the initial report filed under the early warning reporting rules by the Acquiror following the closing of Verano’s reverse take-over going public transaction (the “RTO”). Prior to the RTO, the Acquiror did not have any SV Shares or PV Shares.

See the original post:
George Archos Reports Holdings in Verano Holdings Corp.

Read More...

Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

Sunday, February 14th, 2021

NEW YORK and MAINZ, GERMANY, February 12, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.

Read more:
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

Read More...

Vistin Pharma ASA: Invitation to Q4 2020 conference call

Sunday, February 14th, 2021

Oslo, Norway, 12 February 2020

Continue reading here:
Vistin Pharma ASA: Invitation to Q4 2020 conference call

Read More...

Vericel Announces Termination of Shareholder Rights Agreement

Sunday, February 14th, 2021

CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company’s shareholder rights agreement, commonly referred to as a “poison pill”, which was originally scheduled to expire on August 15, 2021. The shareholder rights agreement was amended to accelerate the expiration date to February 11, 2021, effectively terminating the plan as of that date.

Originally posted here:
Vericel Announces Termination of Shareholder Rights Agreement

Read More...

Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Sunday, February 14th, 2021

JERSEY, Channel Islands, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18.

The rest is here:
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Read More...

Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Sunday, February 14th, 2021

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET

Original post:
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Read More...

Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021

Sunday, February 14th, 2021

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2020 Fourth Quarter and Full-year Earnings Conference Call on Friday, February 26, 2021 at 8:30 a.m. EST. Cronos Group’s senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

Read more:
Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021

Read More...

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Sunday, February 14th, 2021

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000 (the “Offering”), which includes the exercise in full of the 15% over-allotment option. The syndicate of underwriters was led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (together, the "Underwriters"). The Units were offered and sold by way of a short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec.

See the original post here:
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Read More...

Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

Sunday, February 14th, 2021

AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

View post:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

Read More...

Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Sunday, February 14th, 2021

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Continued here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Read More...

Delisting of AS „Grindeks” shares from the Baltic Main list

Sunday, February 14th, 2021

Delisting of AS „Grindeks” shares from the Baltic Main list

Go here to see the original:
Delisting of AS „Grindeks” shares from the Baltic Main list

Read More...

Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

Sunday, February 14th, 2021

NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced development of its 1st full spectrum Cannabidiol (“CBD”) infused edibles product line.  The Company plans to develop this above referenced product line, with the following attributes: Kosher Certified, Halal Certified, Vegan Formulation, Dairy-Free, Infused with Full Spectrum Hemp Extract (“Full Spectrum”), All-Natural Flavors, Sugar Free/Diabetic Friendly Version(s), and Full Adherence to U.S. Federal Laws & Regulations.  The Company expects to provide concrete details about this proposed full spectrum product line within the near term.

See the original post here:
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

Read More...

Radius Health, Inc. Provides Abaloparatide Business Update

Sunday, February 14th, 2021

BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas.

More here:
Radius Health, Inc. Provides Abaloparatide Business Update

Read More...

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three…

Sunday, February 14th, 2021

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects

Continued here:
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three...

Read More...

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the…

Sunday, February 14th, 2021

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use

Here is the original post:
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the...

Read More...

Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium…

Sunday, February 14th, 2021

Continue reading here:
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium...

Read More...

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

Sunday, February 14th, 2021

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

See the original post:
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

Read More...

Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

Sunday, February 14th, 2021

Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.

Here is the original post:
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

Read More...

Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn

Sunday, February 14th, 2021

Here is the original post:
Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn

Read More...

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

Sunday, February 14th, 2021

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

See the rest here:
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

Read More...

Page 11234..10..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick